Meirav Kedmi

Ramat Gan, TA, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Cladribine-based salvage therapy in relapsed/refractory AML: A multicenter retrospective study.

Cladribine-based salvage therapy in relapsed/refractory AML: A multicenter retrospective study.

Journal: Leukemia research
Published: June 07, 2026

Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.

Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.

Journal: British journal of haematology
Published: March 31, 2026

Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies.

Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies.

Journal: Molecular therapy. Methods & clinical development
Published: June 10, 2025

Nivolumab Maintenance for Aggressive B-Cell Lymphoma in Remission After First Line Therapy: A Phase 2 Clinical Trial.

Nivolumab Maintenance for Aggressive B-Cell Lymphoma in Remission After First Line Therapy: A Phase 2 Clinical Trial.

Journal: European journal of haematology
Published: April 30, 2025

Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II study.

Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II study.

Journal: British journal of haematology
Published: March 08, 2025

Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective study.

Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective study.

Journal: Annals of hematology
Published: February 25, 2025

Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells.

Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells.

Journal: Blood advances
Published: August 14, 2024

A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics.

A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics.

Journal: Nature medicine
Published: May 01, 2024

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma.

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma.

Journal: Hematological oncology
Published: March 05, 2024

Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma.

Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma.

Journal: Leukemia & lymphoma
Published: August 11, 2023

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.

Journal: Nature medicine
Published: July 07, 2023

IGHV allele similarity clustering improves genotype inference from adaptive immune receptor repertoire sequencing data.

IGHV allele similarity clustering improves genotype inference from adaptive immune receptor repertoire sequencing data.

Journal: Nucleic acids research
Published: January 03, 2023
Showing 1-12 of 38

Last Updated: 09/26/2026